Synthesis of a New Series of Anthraquinone-Linked Cyclopentanone Derivatives: Investigating the Antioxidant, Antibacterial, Cytotoxic and Tyrosinase Inhibitory Activities of the Mushroom Tyrosinase Enzyme Using Molecular Docking

Abstract

Purpose

New bioactive anthraquinone derivatives are investigated for antibacterial, tyrosinase inhibitory, antioxidant cytotoxic activity, and molecular docking.

Methods

The compounds were produced using the grindstone method, yielding 69 to 89%. These compounds were analyzed using IR, ¹H, and ¹³C NMR and elemental and mass spectral methods. Additionally, the antibacterial, antioxidant, and tyrosinase inhibitory activities of all the synthesised compounds were evaluated.

Results

Compound 2 showed remarkable tyrosinase inhibition activity, with an (IC₅₀: 13.45 µg/mL), compared to kojic acid (IC₅₀: 19.40 µg/mL). It also exhibited moderate antioxidant and antibacterial activities with respect to the references BHT and ampicillin, respectively. Kinetic analysis revealed that the tyrosinase inhibitory activity of compound 2 was non-competitive and competitive, whereas that of compound 1 was low. All compounds (1-8) were significantly less active than doxorubicin (LC₅₀: 0.74±0.01μg/mL). However, compound 2 affinity for the 2Y9X protein was lower than kojic acid, with a lower docking score (−8.6 kcal/mol compared to (−4.7 kcal/mol), making it more effective.

Conclusion

All synthesized compounds displayed remarkable antibacterial, tyrosinase inhibitory, antioxidant, and cytotoxic activities, with compound 2 showing exceptional potency as a multitarget agent. Anthraquinone substituent groups may offer the potential for the development of treatments. The derivatives were synthesized using the grindstone method, and their antibacterial, antioxidant, tyrosinase inhibitory, and cytotoxic activities were inspected. Molecular docking and molecular dynamics simulations were performed using compound 2 and kojic acid to validate the results and confirm the stability of the compounds.

Keywords:

• anthraquinone
• tyrosinase enzyme
• antioxidant activity
• molecular docking
• binding affinity
• kojic acid
• antibacterial activity
• cytotoxic activity

Introduction

Innovations in green chemistry can pave the way to environment-friendly processes and products with uncompromised bio-efficacy. Anthraquinone is an oxygen reduction reaction (ORR) catalyst due to its efficient redox capacity.^1,2 The synthesis of hydrogen peroxide for industrial use mainly depends on anthraquinone because it selectively reduces oxygen molecules to hydroperoxide radicals, and 10-hydroxy-9-anthraxyl radicals are formed, which then undergo hydrogen abstraction, ultimately producing hydrogen peroxide and anthraquinone.^1,3 Fused heterocyclic systems can be found in various pharmaceutically essential formulations and also in some natural products; many of them contain indeno furans, which are known to possess antibacterial and free radical scavenging properties. The indene derivatives are also well-known for their antibacterial properties.⁴ Diethyl 4-cyano-2-hydroxy-5-oxo-4,5-dihydroindeno[1,2-b]pyran-3,4-dicarboxylate (13.2%) and diethyl-2,20-(1,3-dioxo-2,3-dihydro-1H-indene-2,2-diyl)bis(2-cyano acetate)₂ (15%) were two crystalline solid products.^5,6 Phytoalexins of plant origin are used in the treatment of various infectious diseases caused by different etiological agents.⁷ Medical researchers have closely examined the diverse biological activities of many plant-derived molecules and marine natural products.⁸ The controversy surrounding kojic acid stems from its toxicity.⁹ Anthraquinone, a compound widely used in the cosmetic, medical, and agricultural industries, needs effective tyrosinase inhibitors with nominal side effects.¹⁰

Anthraquinone and its derivatives have been found to exhibit a variety of pharmacological effects, including anticancer,¹¹ anti-inflammatories,¹² antifungal,¹³ antibacterial,¹⁴ antiplatelet,¹⁵ and neuroprotective properties.¹⁶ Furthermore, these compounds exhibit desirable characteristics, such as significant emission, excitation, and absorption coefficients for visible wavelengths, as well as low toxicity.^17,18 Some of the natural products which are 2.3-dihydro-1 H inden-1-one are shown in Figure 1. Some of the natural products, 2.3-dihydro-1 H inden-1-one, are shown in Figure 1

Figure 1 Typical natural products based on 2.3-dihydro-1 H inden-1-one.

Tyrosinase, an enzyme frequently present in nature, is reported to have a dinuclear copper core and possesses several functions (EC 1.14.18.1). It is often used to manufacture polyphenolic compounds and pigments like melanin.¹¹ The catalytic mechanism involving tyrosinase in the oxidation of phenols and diphenols depends on the active site, copper.¹⁹ The copper present in this enzyme is responsible for its impressive catalytic activity in the first two steps, which involves the conversion of L-tyrosine into melanin. The process involves hydroxylating L-tyrosine to create L-dihydroxyphenylalanine (L-DOPA), which is further oxidized to form dopaquinone.²⁰

Tyrosinase and similar proteins are synthesized in the rough endoplasmic reticulum. However, tyrosinase possesses some specificity related to malignant melanoma and enzymatic browning in mammals. Developing new and safer tyrosinase inhibitors is necessary for various applications across industries, such as food, cosmetics, dermatological products, and some medicines. Unfortunately, the number of inhibitors found suitable for clinical applications and skin whitening is limited; hence, there is a need for a continued search for natural and synthetic tyrosinase inhibitors. A recent review on tyrosinase inhibitors describes this aspect extensively.²¹

On the other hand, the pathophysiology of many diseases is significantly influenced by free radicals, and this is the reason for the growing interest in discovering and developing novel antioxidants that reduce the risk of damages caused by free radicals.^22,23 The use of antioxidants as preservatives in food items and dermatology, especially cosmetics, attracted more outstanding interests.^24–26 Due to their paramount importance as additives or antioxidants used to stop or slow down the natural occurrence of oxidation, they find diverse and extensive applications in producing numerous formulations.²⁷ Therefore, it is pivotal to discover novel tyrosinase inhibitors with enhanced efficacy and nil side effects.²⁴

The purpose of conducting molecular docking studies is to understand better the results of in vitro activity studies, specifically regarding possible substrate preferences and variations in the active site of the target structure.²⁸ We have exploited the crystal structure of PPO3, a tyrosinase from Agaricus bisporus in its deoxy-form that includes an additional unidentified lectin-like subunit by means of anthraquinone-attached cyclopentanone derivatives. The inhibitor tropolone protein data bank (PDB ID code: 2Y9X) was used for this purpose.²⁹ Using modern bioinformatics and cheminformatics tools, it is possible to create new anthraquinone-based chemical entities with a high degree of accuracy in terms of safety and efficacy. Additionally, the growing field of drug repurposing can be applied to discover new therapeutic uses for this scaffold, as given in some recent articles.¹¹

Anthraquinone derivatives are well known for their antibacterial properties, especially against E. coli and S. aureus,^30,31 and also reported to act as antioxidants and exhibit tyrosinase activity.^32,33 Cosmetic products commonly use tyrosinase-inhibiting agents to preserve skin whiteness, and the use of antioxidants for skin lightening is based on the hypothesis involving oxidative processes.³⁴ The levels of phenolic and flavonoid compounds and their capacities for scavenging free radicals and inhibiting tyrosinase activity were closely related. The stronger the scavenging and inhibiting properties against free radicals and tyrosinase, the higher the concentration of antioxidants, such as kojic acid, which is known for its anti-tyrosinase and antioxidant properties.³⁵

In a previous study, an interaction between tyrosinase and antioxidants was reported.³⁶ Therefore, the current study aimed to investigate anthraquinone-connected cyclopentanone derivatives as potential multitarget agents.

Anthraquinone-connected cyclopentanone derivatives were synthesised using the grindstone method, and their antibacterial, antioxidant, tyrosinase inhibitory, and cytotoxic activities were inspected. Compound 2 was subjected to computational studies, including molecular docking and molecular dynamics simulations.

Experimental

Chemistry

A Thermo Scientific Nicolet iS5 FT-IR spectrometer (4000–400 cm⁻¹ range) and a Bruker DRX-300 MHz and 75 MHz instrument (for ¹H and ¹³C NMR spectra analysis) were used to record the spectra of compounds. An elemental analyzer was used to determine the percentage of C, H, S, and N. Mass spectral analyses were performed by the hyphenated gas chromatography (GC-MS) Clarus SQ8 model from Perkin Elmer. All preparations were carried out using commercially available, general-purpose solvents and reagents, whereas analyses were performed using spectroscopic-grade solvents.

Synthesis of compound 2,6,11-Trioxo-3-Phenyl-N-(o-Tolyl)-2,3,6,11-Tetrahydro-1H-Cyclopenta[a]anthracene-1-Carboxamide (1)

3-Oxo-N-(o-tolyl)butanamide (0.01 mmol), 1.4-dihydroxyanthracene-9,10-dione (0.01 mmol), and aromatic aldehydes (0.01 mmol) were mixed and ground for an hour at room temperature using the grindstone method. Thin layer chromatography (TLC) was used to determine the formation of new products after the reactions. The mixture was separated and purified by column chromatography using a solvent combination of ethyl acetate and hexane in a ratio of 4:6. All other compounds (2–8) were synthesised using the above method.

Yield 72%; mp 149°C; IR (cm⁻¹): 2987 (Ar-NH), 3296 (NH), 1743 (C=O); ¹H NMR (300MHz, DMSO-d₆): 8.29–7.88 (4H, Ar, d); 7.57–7.40 (d, Ar, 2H); 7.38–7.07 (4H, d, Ar); 7.23–6.77 (ph, m, 5H); 7.23 (1H, s, -NH); 4.92 (s, 2H, -CH₂); 4.58 (s, CH₂, 2H); 2.11 (s, -CH, 1H); ¹³C NMR (75 MHz, DMSO-d₆): 206.0 (1C, -C=O); 185.2–182.1 (2C, C=O); 147.2–128.9 (6C, Ar ring); 168.2 (1C, C=O); 147.2–128.9 (6C, Ar ring); 136.2–125.0 (6C, C=O); 133.6–126.8 (6C, Ar ring); 58.9 (1C, C=O); 58.4 (1C, -CH); 17.3 (1C, -CH₃); EI-MS (m/z): 472.15 (M⁺, 33.9%); Elemental analysis: CalcdFor (C₃₁H₂₁NO₄): C, 78.97; H, 4.49; N, 2.97% Found: C, 78.96; H, 4.52; N, 2.94%.

The spectral data of compounds (2–8) were reported in the Figures S1-S16 Supporting Information.

Biological Screening

Tyrosinase Inhibitory Activity

A modified spectrophotometric method was employed to estimate the anti-tyrosinase activity using L-dopa as a substrate. All compounds (1–8) were dissolved in dimethyl sulfoxide (DMSO) to attain the required dilution . The mixture used in the reaction had a final volume of 3.0 mL and contained 1.5 mM L-DOPA, 0.1 mM sodium phosphate buffer with a pH of 6.5, and 12.42 U of mushroom tyrosinase. This mixture was preheated at 30°C and incubated for two minutes. The extent of dopachrome formation was determined by measuring the spectrophotometric absorbance at 475 nm using a Perkin Lambda 35 UV/VIS Spectrometer. Kojic acid was used as a positive control. The following expression gives the proportion of the inhibitory tyrosinase activity:

The absorbance values of the control solution before and after incubation are denoted as A and B, respectively, whereas the absorbance values of the sample solution before and after incubation are denoted as C and D, respectively.³⁷

Antioxidant Activity

The addition of an antioxidant to a 1.1-diphenylpicrylhyrazyl (DPPH) solution in methanol at 517 nm causes the loss of the vibrant purple colour and a reduction in absorption. This indicates that the amount of residual 1.1-diphenylpicrylhyrazyl (DPPH) is inversely proportional to the level of antioxidant activity. The test compounds were added to 0.004% (w/v) methanolic solutions of 1.1-diphenylpicrylhyrazyl (DPPH) (4 mL) at various concentrations (25 or 100 µg/mL in methanol). The absorbance at 517 nm was measured after a 30-minute incubation period, and the percentage inhibition was calculated using the following formula:³⁸

Where, A sample: absorbance of the sample, A control: absorbance of DPPH solutions (except the test material, which contains all compounds); tests were carried out in triplicate.

Antibacterial Activity

The antibacterial properties of the compounds were evaluated using the disc diffusion method, in which the compounds were dissolved in dimethyl sulfoxide (DMSO) at a concentration of 100 μg/mL. They were then impregnated into discs made of sterile filter paper (8 mm in diameter). Two type culture isolates were included, such as S. aureus (MTCC 96) and E. coli (MTCC 739). The bacterial test samples were prepared using sterile saline solution and pure colonies and the density was adjusted to reach a turbidity level of 0.5 McFarland standards. The test organisms were swabbed evenly over Mueller-Hinton agar and exposed to a concentration gradient of compounds diffused from the impregnated paper disc into the agar medium. The inoculated and incubated plates were measured to find the zone of inhibition using ampicillin as a reference after a 24-hour incubation period at 37^°C.^32,39

Minimum Inhibitory Concentration (MIC) Studies

The minimum inhibitory concentrations (MIC) of eight compounds were determined as shown in Table 3. The MIC, which signifies the lowest concentration of the microbial suspension that prevents visible growth of microorganisms, was determined by adding 10⁶ CFU/mL to each well and then incubating the plates at 36°C for 24 h after preventing the visible growth of microorganisms.

Cytotoxic Activity

In a previous study, the cytotoxicity of the newly developed compounds (1–8) was evaluated. The details of the experimental procedure are explained in a different context.³⁹

Statistical Analysis

All experiments were conducted in triplicate to ensure statistically validate the results. The data are represented as the mean standard deviation (S.D.) using the SPSS 25 version.

Molecular Docking Analysis

Molecular docking experiments were performed using Schrödinger Maestro 9.2³⁹ to investigate the interactions and connections between the components of compound 1 and kojic acid, which is part of the most efficient anthraquinone series, with the proteins.

Ligand Preparation

The compound structures (1–8) were designed using ChemDraw 12.0 and Chem3Dpro, which were subsequently employed in the creation of a Protein Data Bank (PDB) for docking studies.

Receptor Preparation

The structure of the mosquito odourant-binding protein, which included water and ligands, was obtained from a protein database. To remove these, Discovery Studio 2019 was used, leaving only the receptors. To lower the energy of the receptor, the SWISS PDB Viewer was utilised, followed by a molecular docking process at the receptor.⁴⁰

Identification of the Binding Pocket

The co-crystallised ligand and Discovery Studio 2019 software were used to determine the presence of Asp 438, Asn 323, and Asn 332 residues within the pocket of the target protein.

Molecular Dynamics Simulation

Molecular dynamics simulations were performed using Desmond from Schrodinger Biosuite to assess the stability of the docked complexes identified through IFD analysis.⁴¹

Results and Discussion

Chemistry

By employing the Mannich base approach, multicomponent derivatives of anthraquinone were synthesized (one-pot synthesis). It was achieved through solvent-free green chemistry, as indicated in Scheme 1. FT-IR, ¹H, and ¹³C NMR spectroscopies were employed to chemically analyse the target compounds. The IR spectra revealed significant bands at 2987–2665 cm⁻¹, 3296–3168 cm⁻¹, and 3296–3168 cm⁻¹, which corresponded to the -Ar, -NH, and -CO groups, respectively. The aromatic rings, -Ar, -Ph, and –CH and -NH, were 8.29–6.80, 7.47–4.0, 4.77–4.58, and 7.17–4.64, respectively, in the proton NMR spectra. In the ¹³C NMR spectra, peaks were observed at 206.0–54.5, 145.9–113.5, 140.3–21.9, 78.7–54.2, and 21.3–54.8 ppm; corresponding to the -Ph ring, -CH, -Ar ring, -CH₃, -C=O, and -O-CH carbon, respectively. The results of elemental analysis and mass spectral patterns of each compound synthesized were perfectly consistent. All the data are available in the Figures S1-S16 Supporting Information.

Scheme 1 The synthesis of anthraquinone- cyclopentanone derivatives (1–8).

Tyrosinase Inhibitory Activity

The tyrosinase inhibitory activity of various compounds was assessed using L-dihydroxyphenylalanine (L-DOPA) as a substrate, and the resulting percentage of inhibition is shown in Figures 2–4. The test results of synthesized compounds were exactly opposite to those found for the inhibition of melanin formation.^42,43 The tyrosinase inhibitory activity of all synthesised compounds was evaluated using L-DOPA as the substrate by modifying a method previously reported by our research team, with slight modifications. This was done to evaluate their tyrosinase inhibitory activity.⁴⁴ Blocking the tyrosinase function requires a 4-hydroxyphenyl maollugin moiety with the correct species and placement of substituents in this series. Compound 2 showed an IC₅₀: 13.45 μg/mL and was significantly more effective than kojic acid, having an IC₅₀: 19.40 μg/mL, and these results are shown in Table 1.

Table 1 Tyrosinase from Mushrooms Inhibitory Functions of Substances (1–8) and Standard Kojic Acid

Compound No.	Concentration (µg/mL)^a			IC50 (µg/mL)
	25	50	100
1	13.72 ± 0.02	49.30 ± 1.06	51.23 ± 0.23	77.62 ± 1.20
2	62.12 ± 0.12	70.00 ± 1.09	86.21 ± 1.52	13.45 ± 0.24
3	21.20 ± 0.23	28.11 ± 0.23	51.61 ± 1.06	87.31 ± 1.84
4	28.75 ± 0.21	61.87 ± 1.32	75.00 ± 1.36	42.65 ± 1.04
5	43.23 ± 0.15	55.21 ± 0.26	64.30 ± 1.52	63.22 ± 0.19
6	20.20 ± 0.11	28.12 ± 0.80	45.60 ± 0.26	>100
7	33.16 ± 1.0	41.95 ± 0.46	50.60 ± 1.08	99.98 ± 0.01
8	10.62 ± 0.52	16.25 ± 0.23	66.25 ± 0.81	80.16 ± 1.36
Kojic acid	56.23 ± 1.12	67.21 ± 1.12	84.65 ± 1.62	19.40 ± 0.74

Note: ^aThe IC₅₀ values represent means ± SE of three different experiments.

Figure 2 Percentage of Tyrosinase Inhibitory activities of synthesized compounds (1–8) at concentration 100 µg/mL.

Figure 3 LineweavereBurk plot for the inhibition of tyrosinase activity by compound 1. Concentrations 0 µM, 21.17 µM, 52.94 µM, 105.89 µM and 211.79 µM were used for analysis compound 1.

Figure 4 Lineweavere Burk plot for the inhibition of tyrosinase activity by compound 2. Concentrations 0 µM, 21.11 µM, 21.17 µM, 52.94 µM and 105.89 µM were used for analysis compound 2.

Inhibitory Mechanism

The oxidation of l-dihydroxyphenylalanine (l-DOPA) by mushroom tyrosinase at various concentrations in relation to compounds 1 and 2 was examined (see Figures S1-S16 Supporting Information for complete details).

Antioxidant Activity

Polyphenolic compounds are known to possess antioxidant properties. The radical-scavenging ability of the synthesised compounds was measured at 517 nm using a Perkin Lambda 35 UV/VIS Spectrometer, which detects phenolic hydroxyl groups. The 1.1-diphenylpicrylhyrazyl (DPPH) method was used to assess the free radical scavenging ability of the samples, with BHT serving as the reference compound and the samples were tested at concentrations of 25, 50, and 100 µg/mL.³² Additionally, the synthesised anthraquinone-cyclopentanone derivatives (1–8) were analysed for their ability to directly scavenge harmful nitrogen and oxygen-containing molecules, including 1.1-diphenylpicrylhyrazyl (DPPH). The results of the free radical scavenging activities are presented in Table 2, which displays the IC₅₀ values and percentage inhibition for each synthetic substance. It was observed that all the synthesised compounds exhibited fair to excellent performance in 1.1-diphenylpicrylhyrazyl (DPPH) assays, demonstrating their potentials. The compound 6 has the lowest activity (36.91 μg/mL), while compound 1 has the highest (58.11 μg/mL), compared to standard BHT (IC₅₀ = 83.45 μg/mL the results are shown in Table 2.

Table 2 Antioxidant Activity of Compounds (1–8)

Compound No.	Percentage of Activity (%)
	/mL
1	58.11
2	39.08
3	47.98
4	40.33
5	40.84
6	36.91
7	37.53
8	52.74
BHT	83.45

Antibacterial Studies

The antibacterial test results revealed that all compounds from (1–8) produced various degrees of inhibition ranging from 8 to 12 mm in diameter. The activity was relatively higher for the reference drug ampicillin, 23 and 17 mm. A negative control test using dimethyl sulfoxide (DMSO) demonstrated no inhibitory activity, proving that the solvent had no impact on bacterial growth (Table 3).⁴⁵

Table 3 Antibacterial Activities of Synthesized Compounds (1–8)

Compound No. (μg/mL)	Diameter of Growth Inhibition Zone (mm)^a (Minimal Inhibitory Concentration (MIC, µg/mL)^b
	Gram-Positive Bacteria	Gram-Negative Bacteria
	S. aureus	E. coli
1	10(64)	– (>100)
2	10(64)	8 (>100)
3	8(>100)	– (>100)
4	8(>100)	– (>100)
5	12(64)	10(64)
6	12(64)	8(>100)
7	11(64)	8(>100)
8	11(64)	8(>100)
Ampicillin	23(0.5)	17 (1)
DMSO	–	–

Note: ^aData are shown as mean ± SD of three independent experiments.

Abbreviation: ^bMIC, minimal inhibitory concentration.

Cytotoxic Activity

The synthesised compounds (1–8) were assessed for their cytotoxic effects against both MCF-7 and Vero cell lines, with all of them demonstrating low activity when compared to the standard drug doxorubicin (LC₅₀:0.74 ± 0.01 μg/mL) as indicated in Table 4 (see Figures S1-S16 Supporting Information for comprehensive details). The Vero cell line was selected based on previous studies.^44,46

Table 4 Cytotoxic Activities of Compounds (1–8)

Compounds	MCF-7			Normal Vero Cell Line	SI^b
	GI50 (µM)	TGI (µM)	LC50 (µM)	LC50(µg/mL)^a
1	34.60 ± 0. 65	60.1± 0.09	87.0± 0.16	93.01± 0.05	1.06
2	45.90± 0.43	67.4 ± 0.06	82.34± 0.16	91.03 ± 0.05	1.10
3	22.96 ± 0.03	45.28± 0.12	63.06± 0.02	68.12± 0.03	1.08
4	35.80± 0.07	45.34±0.09	55.34± 0.05	80.30 ± 0.01	1.45
5	18.50± 0.04	24.6 ± 0.04	52.67± 0.02	78.33± 0.02	1.48
6	45.20±0.03	67.23±0.19	>100	87.16 ± 0.05	0.86
7	10.3 ± 0.12	18.04 ± 0.16	26.05 ± 0.85	65.60± 0.03	2.51
8	11.62 ± 0.19	22.01 ± 0.08	46.40 ± 0.05	54.96 ± 0.08	1.18
Doxorubicin	0.02 ± 0. 00	0.21± 0. 01	0.74± 0. 01	19.85± 0.02	26.82

Notes: ^aEach value represents the mean ± standard deviation of three experiments. IC₅₀ value normal cell / IC₅₀ value cancer cell.

Abbreviation: ^bSI, Selectivity Index.

Docking

Molecular docking was conducted on compound 2 and kojic acid with 2Y9X, a protein that binds mosquito odourants.⁴⁷ Schrodinger Maestro 9.2 was used to study the interactions (Figures 5 and 6). The Pymol and Discovery Studio tools, which received a score of 8 for thoroughness, were used to evaluate the interactions. Two-dimensional molecular depictions were docked with compound 2 andkojic acid. The docking scores are listed in Table 5. (See Figures S1-S16 Supporting Information for full details)

Table 5 Docked Result of Compound 2 and Drug with 2Y9X Using XP Method

S. No	Compound/Drug	Dock Score	Interacting Residues	Bond Length
1.	2	−8.6	Asp 438	2.52
2.	Kojic acid	−4.7	Asn 323, Asn 332	1.70, 1.78

Figure 5 Molecular docking studies on (A) compound 1 (3D Structure), (B) compound 1 (2D Structure) compound 1 docked with 2Y9X protein.

Figure 6 Molecular docking studies on (A) Kojic acid (3D Structure), (B) Kojic acid (2D Structure) standard Kojic acid docked with 2Y9X protein.

Molecular Dynamics Simulation

Molecular dynamics simulations were performed by Desmond and Schrödinger to dock the complex structures of ligand compound 2 with 2Y9X proteins.⁴⁸ In previous studies, we compared the molecular dynamics simulations to examine the interactions and stability of compounds with native ligands and kojic acid.⁴⁹ The stability and simulation of the complexes were analysed and are depicted in Figures 7–10 (See Figures S1-S16 Supporting Information for full details).

Figure 7 RMSD plot of 2Y9X with compound 2.

Figure 8 RMSF plot of 2Y9Xwith Compound 2.

Figure 9 Histogram of protein-ligand contacts of 2Y9X with compound 2.

Figure 10 Timeline representation of protein-ligand contacts of 2Y9X with compound 2. ^#The Number of conducts.

Structure-Activity Relationships

SAR studies of the anthraquinone ring structure offer valuable information into the essential structural features with predominant biological effects.⁵⁰ SAR studies have enabled the identification of groups that enhance the pharmacokinetics of the synthesised molecules and substituents that are resistant to enzymatic degradation. Some of the observations related to structure-activity relationships are discussed below Table 6. (See Figures S1-S16 Supporting Information for full details)

Table 6 Comparison of Highly Active Compounds and the Structure-Activity Relationship

Compound 1		Compound 2
Tyrosinase Inhibition activities (IC50 (µg/mL)
77.62 ± 1.20		13.45 ± 0.24
Cytotoxic activity
87.0± 0.16		82.34± 0.16
Antioxidant activity (100 µg/mL)
58.11		39.08
Antibacterial activity [mm]
S. aureus	E. coli	S. aureus	E. coli
10	–	10	8

Conclusion

This study reports the synthesis of anthraquinone-cyclopentanone derivatives (1–8) and the evaluation of their 1.1-diphenyl-2-picryl hydroxyl free radical scavenging, tyrosinase inhibitory, antibacterial and cytotoxic activities. Accordingly, compound 2 showed significant activity due to the presence of a hydroxyl moiety, which influenced the inhibitory effect on tyrosinase. In the DPPH free radical scavenging test, the anthraquinone compounds demonstrated a moderate level of activity. However, most of the anthraquinone analogues compound (1–8) showed weaker activity than butylatedhydroxytoluene. The anthraquinone analogues showed a moderate level of antibacterial activity compared with that of the reference antibiotic. All compounds (1–8) were significantly less active than the other compounds, and the standard doxorubicin (LC₅₀:0.74± 0.01μg/mL). Compound 2 showed docking scores of (−8.6 kcal/mol) for the 2Y9X protein and (−4.7 kcal/mol) for kojic acid. Compound 2 is better for launching molecular dynamics simulations to validate the molecular docking study and to confirm the stability of the obtained compounds. Compound 2 was developed based on the concept of a “one drug-multiple targets” strategy, which sought to target multiple disease pathways simultaneously to create a novel therapeutic agent. Further research into the mechanisms involved may increase the likelihood of their development as promising skin-whitening agents.

Disclosure

The authors declare no conflicts of interest in this work.

Acknowledgments

The authors extend their appreciation to the Researchers Supporting Project Number [RSP2024 R393], King Saud University, Riyadh, Saudi Arabia